Abstract
Etiological and clinical heterogeneity is increasingly recognized as a common characteristic of Alzheimer’s disease and related dementias. This heterogeneity complicates diagnosis, treatment, and the design and testing of new drugs. An important line of research is discovery of multimodal biomarkers that will facilitate the targeting of subpopulations with homogeneous pathophysiological signatures. High-throughput ‘omics’ are unbiased data driven techniques that probe the complex etiology of Alzheimer’s disease from multiple levels (e.g. network, cellular, and molecular) and thereby account for pathophysiological heterogeneity in clinical populations. This review focuses on data reduction analyses that identify complementary disease-relevant perturbations for three omics techniques: neuroimaging-based subtypes, metabolomics-derived metabolite panels, and genomics-related polygenic risk scores. Neuroimaging can track accrued neurodegeneration and other sources of network impairments, metabolomics provides a global small-molecule snapshot that is sensitive to ongoing pathological processes, and genomics characterizes relatively invariant genetic risk factors representing key pathways associated with Alzheimer’s disease. Following this focused review, we present a roadmap for assembling these multiomics measurements into a diagnostic tool highly predictive of individual clinical trajectories, to further the goal of personalized medicine in Alzheimer’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This review was performed by members of the Biomarkers Team of the Canadian Consortium on Neurodegeneration in Aging (CCNA; Team Leads: RAD and PB) which is funded by the Canadian Institutes of Health Research (CIHR) and partners. Additional sources of support are as follows. AB is currently supported by a CIHR Postdoctoral Fellowship (funding reference number #152548) and the Courtois Foundation. At the start of the project AB was supported by the Alzheimer Society of Canada Postdoctoral Fellowship. PB is a Research Scholar from the Fonds de recherche du Québec, and is also supported by the Courtois Foundation. SS is supported by the Alzheimer Society of Canada Postdoctoral Fellowship. RAD and GPM are also supported by the U.S. National Institutes of Health (National Institute on Aging, R01 AG008235). SD is a Research Scholar from the Fonds de recherche du Québec - Santué [grant number 30801]. The Consortium d’identification pruécoce de la maladie d’Alzheimer - Quuébec is financed through the Fonds de recherche du Quuébec - Santué / Pfizer Canada Innovation Fund [grant number 25262].
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Not applicable
Abbreviations
- Aβ or Aβ42
- amyloid beta or amyloid beta 42
- APOE
- apolipoprotein E
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative
- CN
- cognitively normal
- FDG
- fluorodeoxyglucose
- fMRI
- functional MRI
- GWAS
- genome-wide association studies
- lvPPA
- logopenic progressive aphasia
- MAF
- minor allele frequency
- MCI
- mild cognitive impairment
- NDDs
- neurodegenerative diseases
- NGS
- next-generation genome sequencing
- PCA
- posterior cortical atrophy
- PET
- positron emission tomography
- PRS
- polygenic risk score
- SNPs
- single nucleotide polymorphisms
